John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.
In Conversation with… John Collinge (link to podcast with listing options)
Article: Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme
TLN_April2022_p342_354 (pdf)
The Lancet Neurology April2022 p342_354 (online)
from The Lancet Neurology
